Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose Defining Study For MK-2206 Combined With Gefitinib In NSCLC Population Enriched With EGFR Mutation

NCT01147211 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT01147211
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01147211 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose Defining Study For MK-2206 Combined With Gefitinib In NSCLC Population Enriched With EGFR Mutation
Lead sponsor
National Taiwan University Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
September 30, 2010
Completion date
December 31, 2013
Enrollment
21 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer